Relationship between Plasma Antioxidants and Thyroid Hormones in Chronic Obstructive Pulmonary Disease

Abstract

Background:

A low-T₃ syndrome is observed in chronic diseases, but its treatment is still debated. Chronic obstructive pulmonary disease (COPD) has not been conclusively studied under this aspect. COPD is a complex condition, which cannot be considered a lung-related disorder, but rather a systemic disease also associated to increased oxidative stress. We evaluated thyroid hormones and antioxidant systems, the lipophilic Coenzyme Q10 (CoQ₁₀) and total antioxidant capacity (TAC) in COPD patients to reveal the presence of a low-T₃ syndrome in COPD and investigate the correlation between thyroid hormones, lung function parameters and antioxidants.

Methods:

We studied: 32 COPD patients and 45 controls, evaluating thyrotropin (TSH), free-triiodotyronine (fT₃), free-tetraiodotyronine (fT₄), CoQ₁₀ (also corrected for cholesterol) and TAC. CoQ₁₀ was assayed by HPLC; TAC by the metmyoglobin-ABTS method and expressed as latency time (LAG) in radical species appearance.

Results:

We found significantly lower LAG values, fT₃ and fT₄ levels and significantly higher TSH in COPD patients vs. controls. LAG values significantly correlated with fT₃ concentration. 12 out of 32 patients exhibited fT₃ levels lower than normal range. So we divided COPD patients in 2 groups on the basis of the fT₃ concentration (normal fT₃ COPD and low fT₃ COPD). We observed lower LAG values in normal fT₃-COPD, compared to healthy subjects, with a further significant reduction in low fT₃-COPD patients. Moreover higher TSH concentration was present in normal fT₃-COPD, compared to healthy subjects, with a further significant increase in low fT₃-COPD patients. CoQ₁₀/cholesterol ratio was higher in low fT₃-COPD vs. normal fT₃-COPD, with a nearly significant difference.

Conclusions:

These data seem to indicate an increased oxidative stress in low fT₃-COPD and a role of fT₃ in modulating antioxidant systems. However low fT₃ levels are joined to metabolic indexes of true hypothyroidism, suggesting that elevated CoQ₁₀ expresses a reduced tissue utilization. These data might suggest the need of thyroid replacement therapy in such a condition.

Key words

oxidative stress - metabolic features - thyroid hormones - antioxidants - non thyroidal illness

• References

• 1 Michalaki M, Vagenakis AG, Makri M et al. Dissociation of the early decline in serum T(3) concentration and serum IL-6 rise and TNF-alpha in nonthyroidal illness syndrome induced by abdominal surgery. J Clin Endocrinol Metab 2001; 86: 4198-4205
• 2 Umpierrez GE. Euthyroid Sick Syndrome. South Med J 2002; 95: 506-513
• 3 Chopra IJ. Clinical review 86: Euthyroid sick syndrome: is it a misnomer?. J Clin Endocrinol Metab 1997; 82: 329-334
• 4 McIver B, Gorman CA. Euthyroid sick syndrome: an overview. Thyroid 1997; 7: 125-132
• 5 Wong TK, Hershman JM. Changes in thyroid function in nonthyroidal illness. Trends Endocrinol Metab 1992; 3: 8-12
• 6 Laghi F, Adiguzel N, Tobin MJ. Endocrinological derangements in COPD. Eur Respir J 2009; 34: 975-996
• 7 Creutzberg EC, Casaburi R. Endocrinological disturbances in chronic obstructive pulmonary disease. Eur Respir J 2003; 22 (Suppl. 46) 76 s-80 s
• 8 Dimopolou I, Ilias I, Mastorakos G et al. Effects of severity of chronic obstructive pulmonary disease on thyroid function. Metabolism Clin Exper 2001; 50: 1397-1401
• 9 Okutan O, Kartaloglu Z, Onde ME et al. Pulmonary function tests and thyroid hormone concentrations in patients with chronic ostructive pulmonary disease. Med Princ Pract 2004; 13: 126-128
• 10 Karadag F, Ozcan H, Karul AB et al. Correlates of non-thyroidal illness syndrome in chronic ostructive pulmonary disease. Respir Med 2007; 101: 1439-1446
• 11 Bratel T, Wennlund A, Carlstrom K. Impact of hypoxaemia on neuroendocrine function and catecholamine secretion in chronic obstructive pulmonary disease (COPD): Effects of long-term oxygen treatment. Respir Med 2000; 94: 1221-1228
• 12 Couillard A, Prefaut C. From muscle disuse to myopathy in COPD: potential contribution of oxidative stress. Eur Respir J 2005; 26: 703-719
• 13 Ito K, Barnes PJ. COPD as a disease of accelerated lung aging. Chest 2009; 135: 173-180
• 14 Mancini A, De Marinis L, Calabrò F et al. Physiopathological relevance of Coenzyme Q10 in thyroid disorders: CoQ10 concentrations in normal and diseased human thyroid tissue. In: Folkers K, Littarru GP, Yamagami T. (eds.). Biomedical and clinical aspects of Coenzyme Q. Amsterdam: Elsevier; 1991: 441-448
• 15 Mancini A, De Marinis L, Calabrò F et al. Evaluation of metabolic status in amiodarone-induced thyroid disorders: plasma coenzyme Q10 determination. J Endocrinol Invest 1989; 12: 511-516
• 16 Mancini A, Corbo GM, Gaballo A et al. Relationships between plasma CoQ10 levels and thyroid hormones in chronic obstrucive pulmonary disease. Biofactors 2005; 25: 201-204
• 17 Prior RL, Cao G. In vivo total antioxidant capacity: comparison of different analytical methods. Free Rad Biol Med 1999; 27: 1173-1181
• 18 Bartoz G. Total antioxidant capacity. Adv Clin Chem 2003; 37: 219-292
• 19 Thomas ST, Leichtweis SB, Pettersson K et al. Dietary cosupplementation with vitamin E and CoQ₁₀ inhibits atherosclerosis in apolipoprotein E gene knockout mice. Arterioscler Thromb Vasc Biol 2001; 21: 585-593
• 20 Singh RB, Neki NS, Kartikey K. Effect of coenzyme Q₁₀ on risk of atherosclerosis in patients with recent myocardial infarction. Mol Cell Biochem 2003; 246: 75-82
• 21 Yalcin A, Kilinc E, Sagcan A et al. Coenzyme Q₁₀ concentrations in coronary artery disease. Clin Biochem 2004; 37: 706-709
• 22 Koroshetz WJ, Jenkins BG, Rosen BR et al. Assessment of energy metabolism defects in Huntington’s disease and possible therapy with coenzyme Q₁₀ . Ann Neurol 1997; 41: 160-165
• 23 Beal MF, Matthews RT. Coenzyme Q₁₀ in the Central nervous System and its Potential Usefulness in the Treatment of Neurodegenerative Diseases. Mol Aspects Med 1997; 18: 169-179
• 24 Mosca F, Fattorini D, Bompadre S et al. Assay of coenzyme Q10 in plasma by a single dilution step. Anal Biochem 2002; 305: 49-54
• 25 Tomasetti M, Alleva R, Solenghi MD et al. Distribution of antioxidants among blood components and lipoproteins: significance of lipids/CoQ₁₀ ratio as a possible marker of increased risk for atherosclerosis. Biofactors 1999; 9: 231-240
• 26 Meucci E, Milardi D, Mordente A et al. Total antioxidant capacity in patients with varicoceles. Fertil Steril 2003; 79 (Suppl. 03) 1577-1583
• 27 Rice-Evans C, Miller NJ. Total antioxidant status in plasma and body fluids. Met Enzymol 1994; 234: 279-293
• 28 Scoscia E, Baglioni S, Eslami A et al. Low triiodothyronine (T3) state: a predictor of outcome in respiratory failure? Results of a clinical pilot study. Eur J Endocrinol 2004; 151: 557-560
• 29 Pechatnikov LM. Significance of hypophyseo-thyroid disorders in chronic obstructive bronchitis. Klin Med (Mosk) 1989; 67: 40-43
• 30 Gow SM, Seth J, Beckett GJ et al. Thyroid function and endocrine abnormalities in elderly patients with severe chronic obstructive pulmonary disease. Thorax 1987; 42: 520-525
• 31 Banks WA, Cooper JA. Hypoxia and hypercarbia of chronic lung disease: Minimal effects on anterior pituitary function. South Med J 1990; 83: 290-293
• 32 De Groot LJ. “Non-thyroidal illness syndrome” is a manifestation of hypothalamic-pituitary dysfunction, and in view of current evidence, should be treated with appropriate replacement therapies. Crit Care Clin 2006; 22: 57-86
• 33 Brent GA, Hershman JM, Reed AW et al. Serum angiotensin converting enzyme in severe non thyroidal illness associated with low serum thyroxine concentration. Ann Int Med 1986; 100: 680-683
• 34 Seppel T, Becker A, Lippert F et al. Serum sex hormone-binding globulin and osteocalcin in systemic nonthyroidal illness associated with low thyroid hormone concentrations. J Clin Endocrinol Metab 1996; 81: 1663-1665
• 35 Chopra IJ. An assessment of daily production and significance of thyroidal secretion of 3,3′,5′-triiodothyronine (reverse T3) in man. J Endocrinol Invest 1976; 58: 32-40
• 36 Hepner GW, Chopra IJ. Serum thyroid hormone levels in patients with liver diseases. Arch Int Med 1979; 139: 1117-1120
• 37 Utiger RD. Decreased extrathyroidal triiodothyronine production in non thyroidal illness: benefit or harm?. Am J Med 1980; 69: 807-810
• 38 Van den Berghe GH. The neuroendocrine stress response and modern intensive care: the concept revisited. Burns 1999; 25: 7-16
• 39 Chopra IJ, Chopra U, Smith SR et al. Reciprocal changes in serum concentrations of 3,3′,5-triiodothyronine (T3) in systemic illnesses. J Clin Endocrinol Metab 1975; 41: 1043-1049
• 40 Peeters RP. Non thyroidal illness: to treat or not to treat?. Ann Endocrinol 2007; 68: 224-228
• 41 Arem R, Wiener GJ, Kaplan SG et al. Reduced issue thyroid hormone levels in fatal illness. Metabolism Clin Exp 1993; 42: 1102-1108
• 42 Wehmann RE, Gregerman RI, Burns WH et al. Suppression of thyrotropin in the low-thyroxine state of severe non thyroidal illness. New Engl J Med 1985; 312: 546-552
• 43 Van den Berghe G, De Zecher F, Baxter RC. Neuroendocrinology of prolonged critical illness: Effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues. J Clin Endocrinol Metab 1998; 83: 309-319
• 44 Belchetz PE, Gredley G, Bird D et al. Regulation of thyrotrophin secretion by negative feedback of triiodothyronine on the hypothalamus. J Endocrinol 1978; 76: 439-448
• 45 Steinberg JG, Faucher M, Guillot C et al. Depressed fatigue-induced oxidative stress in chronic hypoxemic humans and rats. Respir Physiol Neurobiol 2004; 141: 179-189
• 46 Faucher M, Steinberg JG, Barbier D et al. Influence of chronic hypoxiemia on peripheral muscle function and oxidative stress in humans. Clin Physiol Funct Imaging 2004; 24: 75-84
• 47 Resch U, Helsel G, Tatzber F et al. Antioxidant status in thyroid dysfunction. Clin Chem Lab Med 2002; 40: 1132-1134
• 48 Asayama K, Kato K. Oxidative muscular injury and its relevance to hyperthyroidism. Free Rad Biol Med 1990; 8: 293-303
• 49 Dobrzynska MM, Baumgartner A, Anderson D. Antioxidants modulate thyroid hormone- and noradrenaline-induced DNA damage in human sperm. Mutagenesis 2004; 19: 325-330
• 50 Venditti P, Di Meo S. Thyroid hormone-induced oxidative stress. Cell Mol Life Sci 2006; 63: 414-434
• 51 Hoch FL. Lipids and thyroid hormones. Prog Lipid Res 1988; 27: 199-270
• 52 Ademoglu E, Gokkusu C, Yarman S et al. The effect of methimazole on oxidants and antioxidants system in patients with hyperthyroidism. Pharmacol Res 1998; 38: 93-96
• 53 Bianchi G, Solaroli E, Zaccheroni V et al. Oxidative stress and anti-oxidant metabolites in patients with hyperthyroidism: effect of treatment. Horm Metab Res 1990; 31: 620-624
• 54 Mancini A, Leone E, Festa R et al. Effects of testosterone on antioxidant systems in male secondary hypogonadism. J Androl 2008; 29: 622-629
• 55 Izumi K, Yoshida M, Terada A et al. Coenzyme Q₁₀ levels in lipoprotein fractions in diabetics. Domyakukoka (Arteriosclerosis) 1982; 10: 671-675
• 56 Keyes WG, Wilcox HG, Heimberg M. Formation of the very low density lipoprotein and metabolism of 1-¹⁴C-oleate by perfused livers from rats treated with triiodothyronine or propylthiouracil. Metabolism Clin Exper 1981; 30: 135-146
• 57 Chait A, Bierman EL, Albers JJ. Regulatory role of triiodothyronine in the degradation of low density lipoprotein by cultured human skin fibroblasts. J Clin Endocrinol Metab 1979; 48: 887-889
• 58 Mancini A, Bianchi A, Fusco A et al. Coenzyme Q₁₀ evaluation in pituitary-adrenal axis: preliminary data. Biofactors 2005; 25: 197-199